替米沙坦和氨氯地平联合罗格列酮治疗2型糖尿病并高血压的临床研究

The Clinic Reasearch of Telmisartan and Amlodipine along with Rosiglitazone on Patients with Type 2 Diabetes and Hypertension

目的:比较氨氯地平、替米沙坦对2型糖尿病并高血压患者血压以及代谢指标的控制效果。方法:45例2型糖尿病并高血压的患者随机分为A、B两组,A组接受替米沙坦和罗格列酮治疗;B组接受氨氯地平和罗格列酮治疗。结果:经6个月治疗后,两组血压水平均有明显下降,血糖和胰岛素抵抗均得到一定改善,但A组血糖、三酰甘油和糖化血红蛋白水平及胰岛素抵抗指数均较B组明显降低,P<0.05。结论:替米沙坦较氨氯地平更能改善2型糖尿病并高血压患者的代谢障碍。

Objective: To compare the effect on glycaemic control of Amlodipine (Amlo) and Telmisartan (Telm) in patients with type 2 diabetes and hypertension. Methods:45 patients with type 2 diabetes and hypertension were assigned to group A and group B randomly. Group A revived Rosiglitazone (RSG) and Telm,and Group B revived RSG and Amlo. Results: After 6 months treatment, both groups showed a significant reduction of blood pressure and a positive influence on glycaemia control and insulin resistance. But blood glucose, TG, HbAlc and HOMA index in group A were significantly lower than those in group B,P < 0.05. Conclusion:In type 2 diabetic hypertensive patients, the association of Telm and RSG seems to display a metabolic advantage compared to Amlo.